Citi Reiterates Buy Rating on Arcturus Therapeutics (ARCT), PT $44, Opens 90-Day Positive Catalyst Watch
Tweet Send to a Friend
Citi analyst Yigal Nochomovitz reiterated a Buy rating and $44.00 price target on Arcturus Therapeutics (NASDAQ: ARCT)The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
